Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study (2014)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- Subjects: BIOMARCADORES; ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS); CO-TERAPIA; TÉCNICAS BIOLÓGICAS
- Language: Inglês
- Imprenta:
- Source:
- Título: Breast Cancer Research
- ISSN: 1465-5411
- Volume/Número/Paginação/Ano: v. 16, n. 4, p. R73, 2014
-
ABNT
SCHNEEWEISS, Andrea et al. Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study. Breast Cancer Research, v. 16, n. 4, p. R73, 2014Tradução . . Disponível em: http://breast-cancer-research.com/content/pdf/bcr3690.pdf. Acesso em: 27 jan. 2026. -
APA
Schneeweiss, A., Chia, S., Hegg, R., Tausch, C., Deb, R., Ratnayake, J., et al. (2014). Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study. Breast Cancer Research, 16( 4), R73. Recuperado de http://breast-cancer-research.com/content/pdf/bcr3690.pdf -
NLM
Schneeweiss A, Chia S, Hegg R, Tausch C, Deb R, Ratnayake J, Mcnally V, Ross G, Kiermaier A, Cortés J. Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study [Internet]. Breast Cancer Research. 2014 ; 16( 4): R73.[citado 2026 jan. 27 ] Available from: http://breast-cancer-research.com/content/pdf/bcr3690.pdf -
Vancouver
Schneeweiss A, Chia S, Hegg R, Tausch C, Deb R, Ratnayake J, Mcnally V, Ross G, Kiermaier A, Cortés J. Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study [Internet]. Breast Cancer Research. 2014 ; 16( 4): R73.[citado 2026 jan. 27 ] Available from: http://breast-cancer-research.com/content/pdf/bcr3690.pdf - Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- Hormonioterapia neoadjuvante no câncer de mama
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Tratamento neoadjuvante no câncer de mama
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- Terapia estrogenica e cancer de mama
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
